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The unique properties of the tumour microenvironment can be exploited by using recombinant anaerobic clostridial spores as highly
selective gene delivery vectors. Although several recombinant Clostridium species have been generated during the past decade, their
efficacy has been limited. Our goal was to substantially improve the prospects of clostridia as a gene delivery vector. Therefore, we
have assessed a series of nitroreductase (NTR) enzymes for their capacity to convert the innocuous CB1954 prodrug to its toxic
derivative. Among the enzymes tested, one showed superior prodrug turnover characteristics. In addition, we established an efficient
gene transfer procedure, based on conjugation, which allows for the first time genetic engineering of Clostridium strains with superior
tumour colonisation properties with high success rates. This conjugation procedure was subsequently used to create a recombinant
C. sporogenes overexpressing the isolated NTR enzyme. Finally, analogous to a clinical setting situation, we have tested the effect of
multiple consecutive treatment cycles, with antibiotic bacterial clearance between cycles. Importantly, this regimen demonstrated that
intravenously administered spores of NTR-recombinant C. sporogenes produced significant antitumour efficacy when combined with
prodrug administration.
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Tumour heterogeneity, particularly with regard to hypoxia and
necrosis, can dramatically limit the effectiveness of anticancer
therapies. Recent analysis has shown that even in small distant
metastasis, large avascular regions are present which can
constitute between 25 and 75% of the tumour mass (Dang et al,
2001). The poorly vascularised, hypoxic cells adjacent to these
areas are difficult to eradicate with conventional treatments and
can also negatively influence the efficacy of novel treatment
strategies. In that context, the limited success of initially exciting
oncolytic adenoviral vectors may be attributed to hypoxia, as the
hypoxia-induced G1 arrest of cells is responsible for lack of viral
replication, thereby rendering these vectors less effective for
anticancer therapy (Pipiya et al, 2005; Shen and Hermiston, 2005).
Similarly, retroviral vectors might also be less effective in hypoxic
conditions, since upon activation of the PERK kinase under
hypoxia, eIF2a gets phosphorylated, leading to overall inhibition of
translation (Koumenis et al, 2002). This defence mechanism
against viral infection and the fact that hypoxic cells do not
proliferate can negatively influence retroviral efficiency under
hypoxic conditions. Perversely, the very existence of these
hypoxic/necrotic regions may provide the solution. This is because
they provide rather ideal environments for the growth and
proliferation of obligate, anaerobic bacteria. Thus, while intra-
venously injected clostridial spores are dispersed throughout the
body, only those that encounter the hypoxic environment of a solid
tumour go on to germinate and multiply (Mose and Mose, 1964;
Carey et al, 1967). Delivery is exquisitely selective, and has led to
the suggestion that clostridia could be used as tumour-specific
vectors for therapeutic gene delivery (Minton et al, 1995; Fox et al,
1996; Lemmon et al, 1997; Lambin et al, 1998).
During the past decade, several recombinant clostridial species
that can express therapeutic proteins specifically in tumours have
been generated (Lemmon et al, 1997; Theys et al, 2001a; Liu et al,
2002; Barbe et al, 2005). Although these reports established the
feasibility of this delivery system and showed some antitumoural
promise, the properties of the strains used were suboptimal,
particularly with respect to tumour colonisation. So far, clostridial
strains able to more effectively colonise tumours, typified by
Clostridium sporogenes, have proven largely recalcitrant to DNA
transfer.
Until now, the principal therapeutic proteins delivered using
clostridial spores have been prodrug converting enzymes (Minton,
2003). These enzymes are characterised by their bystander effect
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sand form the basis of the Clostridium directed-enzyme-prodrug
therapy (CDEPT). In this context, the nitroreductase (NTR) class
of enzymes are of particular interest because their small size
increases the likelihood of efficient clostridial expression. Nitro-
reductase converts the 4-nitrogroup of the prodrug CB1954
(5-aziridinyl-2,4-dinitrobenzamide) to its 10000-fold more toxic
4-hydroxylamine (4HX) derivative, which can be further metabo-
lised to form a DNA–DNA crosslinking and apoptosis-inducing
agent (Palmer et al, 2003). Interestingly, both proliferating and
nonproliferating cells, as they are often present in tumour areas
with gradients of hypoxia, are killed (Cui et al, 1999). The initially
detected rat enzyme (DT-diaphorase), has been superseded by an
enzyme (NTR-B) isolated from Escherichia coli B, due to its
increased activity against CB 1954. However, unlike the rat
enzyme, NTR-B also reduces the 2-nitrogroup to produce the
relatively nontoxic 2-hydroxylamine (2HX) derivative.
Our goal was to substantially improve the prospects of clostridia
by several ways. Firstly, we aimed to improve the enzymatic
conversion of the CB1954 prodrug by isolating a new NTR enzyme
with equivalent or better kinetic parameters to NTR-B, but which
produced only the 4HX derivative of CB 1954. Secondly, we sought
to increase the levels of bacteria, and inherently of therapeutic
protein, in the tumour. This required the development of a method
that allowed efficient gene transfer to strains with enhanced
tumour colonising capacities such as C. sporogenes. Finally, we
intended to evaluate in a quantitative way the ability of the
therapeutic protein delivered by the recombinant clostridia to
convert sufficient levels of prodrug to produce in vivo antitumour
efficacy. To this end, we limited the period of active prodrug
conversion by the metabolically active vegetative recombinant
clostridia in the tumour to a 2-week period by administration of
antibiotics. Analogous to a clinical setting situation, we used this
approach to test the effect of multiple consecutive treatment cycles.
MATERIALS AND METHODS
Bacteria and plasmids
C. sporogenes NCIMB 10696 was obtained from the National
Collection of Industrial and Marine Bacteria (NCIMB Ltd,
Aberdeen, Scotland). The strain was grown in TYG media
(30gl
 1 tryptone, 20gl
 1 yeast extract powder, 1gl
 1 sodium
thioglycollate supplemented with 250mgml
 1 D-cycloserine (to
select for C. sporogenes)) at 371C in an MkIII anaerobic
workstation (Don Whitley, Shipley, UK) with 80% N2, 10% H2,
10% CO2 atmosphere. For general cloning, E. coli TOP10
(Invitrogen, Paisley, UK) was used. The host employed for
expression studies was NovaBlue (DE3). Strains were grown in
Luria-Bertani media at 371C. Media were supplemented, when
applicable, with erythromycin (500mgml
 1 in E. coli or 10mgml
 1
in C. sporogenes), ampicillin (100mgml
 1), tetracycline
(15mgml
 1) or 5-bromo-4-chloro-3-indolyl-b-galactoside (X-Gal;
40mgml
 1). Plasmids used in this study are listed in Table 1.
Isolation of NTR enzymes
Homologues to the previously isolated (Michael et al, 1994;
Anlezark et al, 2002) bacterial NTRs of E. coli (NfnB) and Bacillus
amyloliquefaciens (YwrO) were identified in bacterial genomes
using BLASTP. A total of 10 NfnB-like proteins and five YwrO-like
proteins were selected for further study. DNA encompassing each
encoding gene was amplified from the relevant genomic DNA of
the target organism by PCR using appropriate oligonucleotide
primers and cloned into the expression vector pET21b. In each
case, the 50-primer was designed so that it incorporated an NdeI
restriction site (CATATG), whereby the ATG corresponded to the
translational start codon of the gene. Each gene was inserted into
pET21b at the NdeI site such that translational start codon was
placed at the optimal distance from the vector encoded ribosome-
binding site (RBS). To purify the enzyme, E. coli NovaBlue (DE3)
cells carrying the wild-type (wt) gene were grown overnight at 371C
following induction with IPTG. Recombinant NTR enzymes were
purified to homogeneity as previously described (Anlezark et al,
2002).
NTR assays
Quantitative assays using CB 1954 substrate were carried out at
371C by HPLC as previously described (Anlezark et al, 2002).
When qualitative assays were used to identify column fractions,
the standard conditions were 1mM prodrug, 2mM NAD(P)H, 4%
DMSO in 100mM sodium phosphate buffer pH 7, 371C. Incubation
times varied according to the enzyme activity being studied.
Assays using menadione as substrate were carried out spectro-
photometrically as previously described (Knox et al, 1988) using
cytochrome c as terminal electron acceptor. Similar procedures
were used to assay flavin reductase activity with FMN and FAD as
substrate and with cofactors NADH and/or NADPH. Kinetic
parameters with respect to CB 1954 were determined by HPLC
assay using 10ml of the final product in 500ml assay mix containing
100–1000mM CB 1954, 500mM NADPH and incubating the mixture
at 371C for 10min. Reduction of CB 1954 was determined by
comparison of peak areas at 325nm in standard and enzyme tubes.
Enzyme kinetics were only undertaken on those enzymes found in
qualitative assay to produce predominantly the 4-hydroxlamine
derivative.
In vitro cytotoxicity of CB1954
Microtitre plates (96 well) were obtained preseeded with V79 cells
at 10000cellsml
 1 (European Collection of Animal Cell Cultures,
ECACC) in DMEMþ10% FCS. CB 1954 was dissolved in DMSO
(Sigma, Gillingham, Dorset SP84XT, UK, tissue culture grade) so
that the appropriate concentrations could be dispensed by adding
5ml per well. NAD(P)H was dissolved in sterile PBS to give the
appropriate final concentration by adding 10ml per well. Enzymes
were diluted in sterile PBS. The cells were exposed for 3h to CB
1954 or SN 23862 (3.9–500mM in doubling dilutions) alone or in
combination with cofactor (NAD(P)H 125 or 250mM) and enzyme
(4mg) and subsequently left to incubate at 371C and 5% CO2 for
3–4 days. Cytotoxicity was quantified by sulphorhodamine B
(SRB) assay. Briefly, cells were fixed by adding cold 10% TCA for
30min and washed before adding 0.4% dye in 1% acetic acid and
Table 1 Plasmids used in this study
Plasmid Features Reference
pMTL20E Source of ermB (Oultram et al, 1988)
pMTL4 Shuttle vector backbone (Chambers et al, 1988)
pET21b Expression vector Novagen
pIMP1 pIM13 replicon (Mermelstein et al, 1992)
pMTL6341aLS2 Clostridial expression
cartridge
(Carter et al, 2005)
pMTL20 Cloning vector and
source of LacZa
pMTL30 Source of OriT (Williams et al, 1990)
pCR2.1-TOPO TA PCR cloning vector Invitrogen
pCR-Blunt II-TOPO Blunt PCR cloning vector Invitrogen
pCR4-TOPOHfac2 Source of fac2 promoter Entelechon GmBH
pMTL4-Em Vector backbone – ColEI
Gram-negative replicon+ermB
This study
pMTL552 pMTL4E+pIM13 replicon This study
pMTL553 pMTL552+expression cartridge This study
pMTL554 pMTL553+OriT This study
pEOriT OriT from pMTL30 This study
pMTL555 pMTL554+LacZalpha This study
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sincubating at room temperature for 30min. After washing and air
drying at room temperature the dye was solubilised by adding
100mlo f1 0m M Tris to each well. The plates were read at 492nm in
a Titertek plate reader. Cytotoxicity towards treated cells was
expressed as % of A492 of untreated controls and statistical analysis
was performed using the Mann–Whitney test. ED50s were
calculated using probit analysis.
Construction of the clostridial expression vectors
The erythromycin resistance gene (ermB) from pMTL20E was PCR
amplified using the primers ermBF (50-ATGACTGATATCACT
GATGCTAGCGAAATGATACACCAATCAG-30) and ermBR (50-
CTTAGTGTTAACACAGCTGTAGGCGCTAGGGACCTC-30), and
cloned into pMTL4 digested with EcoRV to generate pMTL4E.
The Gram-positive replicon from pIMP1 was cloned between the
blunt-ended BspHI sites of pMTL4E, deleting the bla gene in the
process. The plasmid obtained was designated pMTL552. The
expression cartridge was obtained from pMTL9341aLS2 and
modified encompassing an altered ferredoxin promoter (fac2) in
which the sequence preceding the ATG start codon had been
replaced with AGGAGGTTAGTCAT, such that the RBS (AGGAGG)
was 8bp away from the ATG start. The entire modified expression
cartridge was then cloned into the EcoRV site of pMTL552, to give
pMTL553. For conjugative mobilisation of the plasmid, a SmaI/
EcoRV fragment carrying the RK2 OriT region was isolated from
the plasmid pEOriT and inserted into the PvuII site of pMTL553
yielding pMTL554. To enable blue/white selection for cloning
purposes, LacZ alpha was cloned in pMTL554 to yield the final
expression vector, pMTL555.
The most effective NTR enzyme identified was YC78_HAEIN of
Haemophilus influenzae, accession Q57431, annotated as a
putative NAD(P)H NTR. A synthetic gene encoding this protein
was synthesised (Entelechon Gmbh, Germany), incorporating
typical Clostridium codons. In parallel, the wt gene was amplified
from the H. influenzae chromosome using the primers HinNTRF
(50-GAGGAAATCATATGACTCAAC-30) and HinNTRR (50-
CTGCAGGCCTTTTTTAAT-30). Both the wt and synthetic gene
were inserted into pMTL555 between the NdeI and PstI sites to
yield pOJP10 and pOJP11, respectively.
Conjugation procedure
Plasmids were introduced into C. sporogenes NCIMB 10696, M-55
and Clostridium novyi-NT (Dang et al, 2001) using a modification
of the protocol previously described by Purdy et al (2002). Briefly,
cells harvested from a 1ml overnight culture of the E. coli donor
were washed in PBS before being resuspended in 200mlo fa n
overnight culture of C. sporogenes or C. novyi-NT grown in TYG
broth. The 200ml mating mix was spotted onto a TYGþ0.5%
glucose (vv
 1) agar plate and incubated anaerobically for 7h. The
mating mixture was subsequently resuspended in 500ml of sterile
PBS before plating onto selective agar (TYGþerythromycin). E.
coli donors were counterselected by the addition of D-cycloserine
(250mgml
 1) to the media. Recombinant colonies of C. sporogenes
NCIMB 10696 were screened for the presence of the plasmid by
PCR and also by retransforming the plasmid back into E. coli
followed by restriction digestion verification of the plasmid.
In vivo evaluation of antitumour effect
Human colorectal carcinoma (HCT116) were injected subcuta-
neously (1.5 10
6 cells) in the abdominal flank of female adult
NMRI nu/nu mice. Tumours were measured at least twice/week in
three orthogonal diameters and volumes calculated according the
formula A B C p/6. All experiments were conducted in
accordance with local institutional guidelines, approved by the
Animal Ethics Committee of the University and procedures were
according to the guidelines defined by the UKCCCR (Workman
et al, 1998).
When tumours reached an average volume of 400mm
3,
treatment was started. Tumour colonisation was allowed f or 5
days before initiation of prodrug and sham treatment, while
selection antibiotics (erythromycin at 60mgl
 1) were added to the
drinking water. CB1954 prodrug (15mgkg
 1) was prepared as
previously described (Djeha et al, 2000) and administrated
intraperitoneally (i.p.) for 5 consecutive days. Animals were
subsequently treated with 200mgkg
 1 Flagyl
s i.p. twice daily
for 9 days. During this period, the drinking water was also
supplemented with Flagyl
s. Body weight measurements were used
as a parameter for treatment toxicity. At the end of the follow-up
period, or when tumours outranged the ethically allowed maximal
volume, animals were killed by cervical dislocation. Tumours and
normal tissues (liver, spleen) were excised, grinded and examined
for colonisation levels at different time points using a procedure
described previously (Lambin et al, 1998).
Statistics
All statistical analyses were performed with SPSS 12.0.1 for
Windows (SPSS Inc., 2003, Chicago, IL, USA). Mixed models
linear regression was used to determine the statistical significance
of differences between two independent groups of variables.
RESULTS
Isolation of novel NTR enzyme
Recombinant procedures were used to produce purified protein
from 10 bacterial homologues of the E. coli NfnB (NTR-B) enzyme
(Michael et al, 1994) and five homologues of YwrO of B.
amyloliquefaciens (Anlezark et al, 2002). Qualitative assays showed
that only one of the YwrO-like enzymes and four of the NfnB
homologues produced predominantly the 4HX derivative of
CB1954. These enzymes were, therefore, subjected to quantitative
analysis and their Km and kcat with CB1954 determined (Table 2).
The enzyme NTR-H isolated from H. influenzae (Accession no.
YP_249310) possessed the most favourable properties. In addition
to producing only the 4HX derivative from CB1954, it had a Km
and kcat for this substrate of 690mM and 56.2s
 1, respectively. This
compares to the previously isolated bacterial enzymes of E. coli B
(NTR-B) and B. amyloliquefaciens (YwrO) which possess a
respective Km of 862 and 618mM and a kcat of 6.0 and 8.2s
 1.
Thus, while the affinity of NTR-H and NTR-B for the prodrug
substrate (Km) is broadly equivalent, the rate at which it is turned
over (kcat) is an order of magnitude greater in the case of NTR-H.
Moreover, the entire reaction product is the toxic 4HX derivative,
as opposed to NTR-B where 50% of the reaction results in the
nontoxic 2HX derivative.
The benefits of these improved properties on cytotoxicity were
demonstrated in a set of experiments in which equivalent
quantities of purified NTR enzyme were incubated with V79 cells
Table 2 Characteristics of purified bacterial nitroreductases
Enzyme Product Km (lM) kcat (s
 1)
ED50 CB
1954 (lM)
NfnB 4HX+2HX 682 6.0 6.3
YwrO BAM 4HX 617 8.2 137.1
YdgI 442HX 3863.9 30.3 15.3
YodC 442HX 552.2 58 20.3
Haemophilus influenzae NfnB 4HX 690 56.2 4.7
Campylobacter jejuni NfnB 4HX 217 6.1 55.8
Porphyromonas gingivalis YwrO 4HX 1200 3.2 252.3
4HX¼4-hydroxylamine.
Multiple CDEPT cycles are effective in vivo
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sin the presence of varying concentrations of CB1954 (Figure 1).
The greatest degree of killing was observed in the case of NTR-H.
In general, with all the enzymes tested (Table 2), ED50 appeared to
be more highly related to kcat as opposed to Km, with NTR-H
proving to be the most potent.
Transformation of Clostridum spp with superior tumour
colonising properties
Having established the superiority of the NTR-H, we sought to
introduce an expression plasmid carrying the gene into the
Clostridium strains with the best tumour colonising properties. A
method of transforming the selected species, C. sporogenes, has
previously been described (Liu et al, 2002). However, repeated
attempts to obtain transformants with this method of two different
C. sporogenes strains and of C. novyi-NT in our laboratories over a
period of 2 years were unsuccessful. We therefore explored the use
of a conjugative procedure, initially developed for the introduction
of plasmids into Clostridium difficile (Purdy et al, 2002).
In our initial experiments we utilised C. sporogenes ATCC 13732
as the recipient, and we were able to show that plasmids could be
consistently introduced at appreciable frequencies. The rate of
transfer varied between 1.5 10
 7 and approaching 1.0 10
 4
transconjugants per recipient, dependant on the plasmid employed
(Table 3). Significantly, for those plasmids tested (Table 3) this
method also proved to be applicable to C. sporogenes M-55 (Mose
and Mose, 1964) and C. novyi-NT (Dang et al, 2001; Bettegowda
et al, 2003), which had previously proven recalcitrant to all
transformation attempts. With this conjugation method, we
obtained success rates of 70–90%, depending on the strain being
used. In all cases, the plasmid could be reisolated by transforma-
tion into E. coli, and its authenticity established through analysis of
suitably restricted samples on agarose gels.
Having derived an efficient gene transfer procedure, we
constructed a purpose built expression vector, pMTL555, in which
two different genes encoding NTR-H were independently cloned
(Figure 2). The first represented the wt gene, the second was a
synthetic gene, in which the codons were changed to match the
Clostridium codon usage. Following the introduction of the two
recombinant plasmids (pOJP10 and pOJP11, wt and synthetic
NTR-H, respectively), verification of the transconjugants indicated
no structural change to either pOJP10 or pOJP11. The levels of
NTR in both recombinant derived samples were significantly
higher compared to wt control samples. As the lysate derived from
cells carrying pOJP11 produced slightly higher levels than cells
harbouring pOJP10, we chose the NTR-H expressing C. sporogenes
strain carrying pOJP11 to evaluate its ability to produce
antitumour activity.
In vivo antitumour activity following systemic
administration of recombinant C. sporogenes
Our aim was to determine whether the levels of NTR-H delivered
by the recombinant C. sporogenes were sufficiently high to cause
enough prodrug conversion to result in measurable antitumour
efficacy. A tumour regrowth delay assay was used to quantify the
magnitude of this effect. Nu/nu mice xenografted with HCT116
were injected with NTR-H expressing C. sporogenes spores when
tumours reached an average volume of 400mm
3. In order to be
potentially useful for the treatment of disseminated or inaccessible
tumours, injections were given systemically rather than through
local injection. Animals were divided into four groups that
received (1) no treatment, (2) CB1954 prodrug alone (15mgkg
 1,
five times a week), (3) recombinant spores (at a concentration of
5.10
7cfu in a volume of 100ml saline via the tail vein) followed by
prodrug vehicle only (sham treatment) or (4) recombinant spores
followed by CB1954 prodrug solution, respectively. To allow
tumour colonisation to take place, prodrug or sham treatment
started at day 5 after spore injection. Although the in vivo
feasibility of the CDEPT approach has been investigated in the
past, it has been difficult to discriminate between the specific effect
of prodrug conversion and the effect of the bacteria only. The main
reason is the continuous presence of recombinant bacteria during
the entire follow-up and consequently, their potential contribution
to the observed antitumour effects. Therefore, in order to
quantitatively evaluate the CDEPT approach, we eradicated the
C. sporogenes form the tumour following the daily prodrug
injections by an antibiotic treatment course (Flagyl
s, 200mgkg
 1,
2  daily, for 9 days). This allowed us to specifically separate the
effects of the recombinant bacteria alone from the effects of the
bacteria in combination with the prodrug.
Tumour colonisation following recombinant spore administra-
tion but before the onset of antibiotic treatment was quantified by
performing dilution series of randomly selected tumours from
spore-treated animals. All tumours investigated showed colonisa-
tion levels of 10
8–10
9cfug
 1 tumour tissue. As expected, viable
clostridia could not be detected in normal tissues. Importantly,
tumour colonisation levels decreased below the detection limit
CB1954 (M)
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Figure 1 Assessment of CB1954 cytotoxicity. Cytotoxicity of CB 1954
was assessed in 96-well plates seeded with V79 cells (10
4 per ml) by
incubating them with CB 1954 alone (3.9–500mM), prodrugþNAD(P)H
(250mM), or prodrug, cofactor and enzyme (4mgwell
 1) for 3h in serum
free DMEM. The medium was replaced and the cells grown for 72–96h
post-treatment in DMEMþ10% FCS until control (untreated) cells had
achieved confluence. The cells were fixed, stained with SRB and the plates
read at 492nm. Results are expressed as % of control (untreated cells).
Key: K, prodrug alone; J, prodrug þNADH; m, prodrugþNADPH; ’,
HinNTRþNAPDHþProdrug; &, NfnBþNADHþprodrug, and; ~,
YwrOþNADPHþprodrug.
Table 3 Transfer frequencies of various plasmids from E. coli donors into
three different clostridial strains
Conjugation efficiency (transconjugants
per recipient strain)
Plasmid (replicon)
C. sporogenes
ATCC 13732
C. sporogenes
M-55 C. novyi-NT
pMTL555 (pIM13) 1.44 10
 7 1.84 10
 7 ND
pMTL9501/pCTC41 (pAMb1) 1.18 10
 6 1.27 10
 6 1.80 10
 7
pMTL9401 (pCB102) 8.86 10
 5 ND ND
pMTL9611 (pIP404) 8.3 10
 6 ND ND
pMTL9301 (pCD6) 4.00 10
 5 ND ND
Plasmids pMTL9301, pMTL9401, pMTL9501 and pMTL9611 are described by Purdy
et al (2002). Plasmid pCTC41 is described by Williams et al (1990).
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sfollowing antibiotic treatment, indicating the efficacy of the
Flagyl
s therapy. As already well established using other NTR-
directed gene therapy approaches (Djeha et al, 2001), CB1954
administration alone had no effect on tumour volumes
(Figure 3A). Administration of spores alone caused a moderate,
but significant tumour growth delay (Po0.0001, mixed linear
regression analysis) (Figure 3A). This was a consequence of
modest tumour lysis and the appearance of haemorrhagic necrosis,
traJ
traJ
Smal
Smal
pMTL555
NTR
4797 bp
Aat II
RNA II
Eco RV
celA T BamHI
BspHI
pIMP1
repL
repL
bla
RNA II
lacZ
lacZ fd T
ermB
fac2
fac2
NdeI
celA T
f
d
 
T
ermB
pAMB1
onT
Pvu II
pMTL4-Em
3132 bp
BspHI
Eco RV
Figure 2 Construction of plasmids overexpressing NTR. The derivation of DNA fragments used to assemble the expression vector pMTL555 is as
indicated. For a detailed description see Materials and Methods. Key: repL, replication protein of pIM13, taken from the derivative plasmid pIMP1, bla, b-
lactamase of pMTL4; ermB, erythromycin resistance gene from plasmid pAMb1; traJ, transfer protein from the ‘origin of transfer’ (oriT) of plasmid RK2;
RNAIII, replication region of ColE1, taken from the derivative plasmid pMTL4; celA T, transcriptional terminator of the Clostridium thermocellum celA gene;
fac2, the promoter of the Clostridium pasteurianum ferredoxin gene, derivatised to include an E. coli lac operator; lacZ, b-galactosidase alpha fragment; fd T,
transcriptional terminator of the C. pasteurianum ferredoxin gene. Gene fragments encompassing NTR enzymes (NRase) are cloned into the lacZ region
using the NdeI site adjacent to the fac2 RBS and an appropriate site (e.g., SmaI) in the pMTL20 polylinker region present in lacZ.
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Figure 3 Antitumour effect following systemic administration of NTR-recombinant C. sporogenes spores to nu/nu mice bearing HCT116 tumours. (A)
Tumour growth after one cycle of recombinant C. sporogenes treatment with CB1954 prodrug (’) or vehicle only (sham) (m) treatment. Control animals
received no treatment (K) or CB1954 alone (.). (B) Representative body weight evolution during a treatment cycle. Data are from at least five mice per
group with error bars showing standard deviations for each group. Tumour volumes are normalised to 100 arbitrary units at the start of the treatment,
allowing comparison of tumour growth within and across groups.
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san observation also made when using other clostridial species such
as C. sporogenes M55 and C. novyi-NT (Dang et al, 2001). When
combined with CB1954 administration, the antitumour effect
significantly increased (Po0.0001, mixed linear regression analy-
sis) (Figure 3A), thereby establishing the in vivo treatment efficacy
of the NTR CDEPT approach. During the treatment, animals in
both treatment arms showed a transient weight loss. This effect
was not significantly different between the two groups. Most
importantly, the observed weight loss was totally reversible and the
animals recovered completely following the antibiotic treatment
(Figure 3B).
In vivo efficacy of repeated CDEPT treatment cycles
In a clinical setting, chemotherapy is typically given in multiple
cycles in order to maximise its effects. Analogous to this situation,
we questioned whether clostridial therapy could be given
repeatedly. A treatment cycle started at the day of spore injection
(day 1), followed 5 days later (day 6) by prodrug or vehicle
treatment for 5 days. Each treatment cycle was then followed by
antibiotic treatment during 9 days. Eventually animals were
allowed to recover for an additional period of 5–7 days. Sham-
treated animals were given two consecutive identical cycles. The
tumour growth delay caused by each of the two (sham) treatment
cycles was very similar (Figure 4). This result indicates not only
that the bacteria can effectively recolonise the tumour to result in
an antitumour effect, but also that the tumour microenvironment
following the first treatment cycle did not fundamentally change.
Despite the observed growth delay within the sham-treated group,
the animals in this group had to be killed for ethical reasons by the
end of the second treatment cycle because their tumour volumes
became too high. In contrast, and more importantly, a highly
significant and much bigger antitumour effect was observed in
animals that were treated twice with recombinant spores combined
with CB1954 prodrug (Figure 4). This allowed application of an
additional third treatment cycle. Throughout the three cycles, the
treatment resulted in sustained growth delay effects.
DISCUSSION
In the current paper, we report significant progress in the use of
clostridia to deliver prodrug-converting enzymes specifically to
tumours. As a first step to improve the system, we isolated a novel
NTR enzyme with better characteristics than NTR enzymes used so
far. The NTR-H enzyme was demonstrated to be the best out of 15
tested bacterial NTR homologues. The enzyme produced only the
toxic 4HX CB1954 derivative and showed the best kinetic
parameters of all the enzymes tested. As expected, the superior
enzyme properties translated into an enhanced toxicity profile in
vitro. To evaluate the in vivo efficacy of this novel enzyme, transfer
of the NTR-H enzyme to a Clostridium strain with enhanced
tumour colonisation properties was absolutely necessary. Indeed,
although previous CDEPT work undoubtedly established the safety
and feasibility of the approach, proof of in vivo antitumour efficacy
has so far been limited (Lemmon et al, 1997; Theys et al, 2001a; Liu
et al, 2002). The major reason for this failure has been attributed to
the low tumour colonisation efficiency of the employed strains.
Until recently, the best tumour colonising strains, such as C.
sporogenes or C. novyi-NT, could not be transformed. Thus, the
reported development a few years ago of a transformation system
based on electroporation for C. sporogenes, was encouraging (Liu
et al, 2002). Unfortunately, the reported transformation procedure
could never be reproduced in our laboratories. As exogenous
endonucleases represent a major impediment to DNA transfer, we
therefore devised a procedure based on conjugative transfer from E.
coli donors. Here, we demonstrate that this procedure can be used
to introduce recombinant plasmids into superior tumour colonis-
ing strains such as C. sporogenes, C. oncolyticum and C. novyi-NT at
high frequencies and with high success rates. Thanks to this
breakthrough, it will now be possible to express essentially any
heterologous gene of interest in these clostridial vectors. As shown
here for NTR-H, the adaptation of the heterologous gene codons to
the codon usage in the clostridial host, characterised by its low
GþC% content, might further increase therapeutic protein yield.
Finally, we evaluated if the recombinant C. sporogenes strain
could deliver enough NTR-H to tumours in vivo to convert
sufficient levels of prodrug to produce antitumour efficacy.
Although in vivo antitumour effects using a CDEPT strategy have
already been demonstrated with recombinant clostridia, it has
been difficult to attribute the observed effects specifically to
prodrug conversion, since the bacteria remain present in the
tumour. As the bacteria have antitumour effects in their own right,
as demonstrated in our work, it is not clear how much of the effect
is due to their continuous presence. We therefore devised a way to
quantify the magnitude of the antitumour effect due to prodrug
conversion by giving pulse treatment cycles, followed by antibiotic
treatment. Clearance of the bacteria from the animal not only
allowed recovery after the treatment cycle, it also enabled a precise
and direct quantification of the antitumour effect. In order to
minimise all secondary effects that could be potentially involved in
mediating the antitumour effect, we chose immunocompromised
mice as a model, although there is no evidence for an immune
response as shown earlier in immunocompetent rats (Theys et al,
2001b). Our results clearly demonstrate that intravenously
administered spores of C. sporogenes expressing NTR-H produce
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Figure 4 Antitumour effect following repeated treatment cycles of
NRase-recombinant C. sporogenes in combination with CB1954 adminis-
tration. Groups were recombinant C. sporogenes treatment with CB1954
prodrug (’) or vehicle only (sham) (m) treatment and control animals,
receiving no treatment (K). The dashed line indicates the expected
tumour growth following one treatment cycle (based on results shown in
Figure 3A). A single treatment cycle consisted of bacterial spore
administration at day 0, followed by CB1954/vehicle administration at
day 6, during 5 days. Each treatment cycle was followed by antibiotic
therapy and an additional recovery period for the animals (for more details,
see legend Figure 3 and text). Sham-treated animals received two
treatment cycles before tumour volumes outranged the ethically allowed
maximum. The CB1954 treated group was given an additional third
treatment cycle. Tumour volumes are normalised to 100 arbitrary units at
the start of the treatment, allowing comparison of tumour growth within
and across groups.
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ssignificant antitumour efficacy when combined with prodrug
administration. Most importantly, highly significant and pro-
longed antitumour efficacy could be obtained following repeated
cycles. As we observe such a striking antitumour response, it must
mean that not only the hypoxic but also aerobic cells are being
killed as a result of an additional bystander effect. Such a
phenomenon has indeed been described for NTR in combination
with CB1954 (Djeha et al, 2000; Wilson et al, 2002). Therefore, the
use of a prodrug activating enzyme not only is a further safeguard
to the system (compared to expression of a direct cytotoxic protein
which might produce host toxicity if it comes in circulation), but
also provides considerable potential for treatment amplification.
To our knowledge, this is the first demonstration of a sustained
antitumour effect following multiple cycles of recombinant
clostridia treatment. Overall, this indicates that maturation of
inactive spores into vegetative rods following a first cycle does not
eliminate the activity of subsequent administrations. Our data are
in line with our own previously reported results (Theys et al,
2001b) and with the observations of Liu et al (2002) showing no
reduction in numbers of vegetative cellsg
 1 tumour occurring
between 7 and 14 days after a single spore injection. This is not
limited to animals with an immunocompromised immune system
since it was demonstrated some 25 years ago that repeated
clostridial spore administration could be performed in tumour-
bearing rats (Gericke et al, 1979). This is likely due to the lack of
immunogenicity of the applied clostridial spores. Moreover,
transition from spores to the vegetative reproductive state only
occurs in the severe hypoxic and necrotic region of the tumour,
considered to be an immune privileged site.
Although the observed effects of the therapy were significant,
additional efficacy would be predicted when combined with
radiotherapy and/or conventional chemotherapy. Other potential
combined treatment modalities include specific targeting of the
structurally abnormal tumour blood vessels with vascular targeting
agents as we (Theys et al, 2001b) and others (Dang et al, 2001)
have already successfully reported. In addition, more soluble
derivatives of CB1954 that cause more effective tumour regression
have recently been described (Wilson et al, 2002) and since 5-FU
and CB1954 have been shown to act synergistically (Palmer et al,
2003), the combinatorial use of prodrug activating enzymes
(CDase and NTR) might be a promising option for CDEPT.
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